PTCT · Ptc Therapeutics, Inc. · Executive Compensation
$63.49
+0.13 (+0.21%)
At close · Nov 13
View the 10-K filed Feb 19, 2026
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Customer concentration
— top 4 customers 10% of revenue
4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
Market Cap
$5.30B
Shares
83.54M
Volume · Nov 13
502.9K
Avg daily vol (3M)
1.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Stuart Peltz | Chief Executive Officer | $7,759,441 |
| Marcio Souza | Chief Operating Officer | $3,709,523 |
| Neil Almstead | Chief Technical Operations Officer | $2,518,769 |
| Mark E. Boulding | Executive Vice President and Chief Legal Officer | $2,509,994 |
| Emily Hill | Chief Financial Officer | $2,336,648 |
| Christine Utter | Senior Vice President, Finance and Chief Accounting Officer | $1,700,118 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stuart Peltz | Chief Executive Officer | $4,016,735 |
| Marcio Souza | Chief Operating Officer | $1,945,002 |
| Neil Almstead | Chief Technical Operations Officer | $1,609,441 |
| Mark E. Boulding | Executive Vice President and Chief Legal Officer | $1,604,903 |
| Christine Utter | Senior Vice President, Finance and Chief Accounting Officer | $1,148,789 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Stuart Peltz | Chief Executive Officer | $2,172,683 |
| Marcio Souza | Chief Operating Officer | $1,524,266 |
| Mark E. Boulding | Executive Vice President and Chief Legal Officer | $1,121,909 |
| Neil Almstead | Chief Technical Operations Officer | $951,918 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hege Sollie-Zetlmayer | director | Appointed | 2026-07-30 |
| Alethia Young | member of the board of directors | Resigned | 2026-06-09 |
| Jessica Chutter | Class I director | Appointed | 2026-03-25 |
| Pierre Gravier | Chief Financial Officer | Appointed | 2023-07-17 |
| Emily Hill | Chief Financial Officer | Terminated | 2023-05-23 |
| Dr. Matthew B. Klein | Chief Executive Officer and President | Appointed | 2023-04-18 |
| Stuart W. Peltz | member of the Board | Retired | 2023-03-24 |
| Stuart W. Peltz | Chief Executive Officer | Retired | 2023-03-24 |
| Matthew B. Klein | Chief Executive Officer and President and a member of the Board | Appointed | 2023-03-24 |
| Dawn Svoronos | member of the board of directors | Resigned | 2022-12-06 |
Leadership
- Dr. Matthew B. Klein CEO, Board Member
- Matthew B. Klein CEO, Board Member
- Matthew Klein CEO, Board Member
- Michael Schmertzler CFO
- Mark E. Boulding General Counsel
- Christine Utter Chief Accounting Officer
- Allan Jacobson Board Member
- David P. Southwell Board Member
- Hege Sollie-Zetlmayer Board Member
- Jessica Chutter Board Member
- William F. Bell Board Member
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
284 filings
256 filers
Visit website
Investor relations